449 related articles for article (PubMed ID: 22032984)
1. Interleukin-15 biology and its therapeutic implications in cancer.
Steel JC; Waldmann TA; Morris JC
Trends Pharmacol Sci; 2012 Jan; 33(1):35-41. PubMed ID: 22032984
[TBL] [Abstract][Full Text] [Related]
2. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
3. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
[TBL] [Abstract][Full Text] [Related]
4. Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.
Hong E; Usiskin IM; Bergamaschi C; Hanlon DJ; Edelson RL; Justesen S; Pavlakis GN; Flavell RA; Fahmy TM
J Biol Chem; 2016 Apr; 291(17):8931-50. PubMed ID: 26719339
[TBL] [Abstract][Full Text] [Related]
5. A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells.
Bosch NC; Martin LM; Voskens CJ; Berking C; Seliger B; Schuler G; Schaft N; Dörrie J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638566
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 15 as a promising candidate for tumor immunotherapy.
Jakobisiak M; Golab J; Lasek W
Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
[TBL] [Abstract][Full Text] [Related]
7. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
8. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.
Elpek KG; Rubinstein MP; Bellemare-Pelletier A; Goldrath AW; Turley SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21647-52. PubMed ID: 21098276
[TBL] [Abstract][Full Text] [Related]
9. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
Stoklasek TA; Schluns KS; Lefrançois L
J Immunol; 2006 Nov; 177(9):6072-80. PubMed ID: 17056533
[TBL] [Abstract][Full Text] [Related]
10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
11. The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO; Schluns KS
Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
[TBL] [Abstract][Full Text] [Related]
12. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
13. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
14. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
15. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
16. IL-15 and HIV infection: lessons for immunotherapy and vaccination.
Ahmad A; Ahmad R; Iannello A; Toma E; Morisset R; Sindhu ST
Curr HIV Res; 2005 Jul; 3(3):261-70. PubMed ID: 16022657
[TBL] [Abstract][Full Text] [Related]
17. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
19. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.
Guo Y; Luan L; Patil NK; Sherwood ER
Cytokine Growth Factor Rev; 2017 Dec; 38():10-21. PubMed ID: 28888485
[TBL] [Abstract][Full Text] [Related]
20. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
Khawam K; Giron-Michel J; Gu Y; Perier A; Giuliani M; Caignard A; Devocelle A; Ferrini S; Fabbi M; Charpentier B; Ludwig A; Chouaib S; Azzarone B; Eid P
Cancer Res; 2009 Feb; 69(4):1561-9. PubMed ID: 19190330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
